Table 2 .
Treatment emergent adverse events
| Patients with | VB-111 + Bevacizumab (n = 126) | Bevacizumab (n = 111) | Overall (n = 237) |
|---|---|---|---|
| N (%) | N (%) | N (%) | |
| Any AE | 125 (99.2) | 107 (96.4) | 232 (97.9) |
| Any serious AE | 65 (51.6) | 33 (29.7) | 98 (41.4) |
| Any VB-111 related AE | 91 (72.2) | 0 | 91 (38.4) |
| Any bevacizumab related AE | 85 (67.5) | 60 (54.1) | 145 (61.2) |
| Any CTCAE grade 3–5 AE | 85 (67.5) | 44 (39.6) | 129 (54.4) |
| Any AE leading to treatment discontinuation | 23 (18.3) | 19 (17.1) | 42 (17.7) |
| Any AE leading to death* | 6 (4.8) | 2 (1.8) | 8 (3.4) |
* Per protocol events which are part of the natural course of the disease under study (ie, disease progression) should not have been reported as AEs and are not included in this row.